Alder BioPharma's new data demonstrated eptinezumab increased migraine-free intervals
Alder announced new data from its PROMISE 1 Phase 3 clinical trial evaluating eptinezumab in patients with episodic migraine. The clinical data demonstrated that patients experienced a significant reduction in migraine days and improved QOL outcomes. April 25, 2018